SUPN stock news
This page provides real-time market news, earnings updates, and company announcements related to Supernus Pharmaceuticals, Inc. (SUPN).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-15 12:40 EST
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Finviz2026-02-12 21:39:08
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
Finviz2026-02-23 03:12:44
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
Finviz2026-02-23 03:12:44
Supernus Pharmaceuticals to Participate in March Investor Conferences
Finviz2026-02-23 23:18:39
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), the purchase price structure for Supernus Pharmaceuticals not only includes the ongoing Phase 2B clinical research, but also potential future milestone payments, with the total amount reaching up to $350 million.
老虎证券2026-04-07 21:41:33
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals officially signed an asset purchase agreement with Navitor on April 1, 2026.
老虎证券2026-04-07 21:41:35
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820).
老虎证券2026-04-07 21:42:30
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), the purchase price structure for Supernus Pharmaceuticals not only includes the ongoing Phase 2B clinical research, but also potential future milestone payments, with the total amount reaching up to $350 million.
老虎证券2026-04-07 21:41:33
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals officially signed an asset purchase agreement with Navitor on April 1, 2026.
老虎证券2026-04-07 21:41:35
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820).
老虎证券2026-04-07 21:42:30
SUPN stock chart
SUPN stock detailsSUPN stock price change
On the last trading day, SUPN stock closed at 49.95 USD, with a price change of -1.44% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more